Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: May 21, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 1615 miles
Mayo Clinic

VISITS: 1 visit per month, ongoing


NCT ID: NCT03941730

Estradiol in Advanced Triple Negative Tumors that Test Positive for ER Beta

Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer Scientific Title

To study the effects (good and bad) of estradiol in the subset of triple negative tumors that test positive for ER beta.
Who is this for?
Women with with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer who have a tumor that tests positive for estrogen receptor beta (ER beta).    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol, by mouth, 3 times a day</li> <li class="seamTextUnorderedListItem">2 biopsies (at the start of treatment and after 1 month)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Early studies suggest that estradiol--a type of estrogen--slows the growth of tumors that are ER-beta positive.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR2</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03941730' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drugs.com/estradiol.html' target='_blank'>Drugs.com: Estradiol</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/30338035' target='_blank'>Pubmed: Estrogen receptor-beta is a potential target for TNBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/centers-programs/cancer-research/research-programs/womens-cancer-program/breast-cancer-spore/research-projects/therapeutic-targeting-estrogen-receptor-beta-triple-negative-breast-cancer' target='_blank'>Mayo Clinic: Therapeutic Targeting Estrogen receptor-beta in TNBC</a> </li></ul>
See more